Poolbeg to engage with key international stakeholders at congress

EMC 2022

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, is participating in the European Melioidosis Congress (EMC) 2022, due to take place 16 May 2022 – 18 May 2022 in Graz, Austria, as it develops a Melioidosis vaccine candidate.

Poolbeg currently holds an option from University College Dublin to licence a late pre-clinical stage Melioidosis vaccine (POLB 003). There is currently no available vaccine on the market for Melioidosis, an infectious disease which is widespread in tropical and subtropical regions such as Northern Australia and Southeast Asia, with rising incidence around the world due to climate change. Caused by the bacteria Burkholderia pseudomallei, Melioidosis is intrinsically resistant to antibiotics and has global mortality rates up to 70%, depending on geography and bacterial load.

Learn more about POLB 003 here.

Jeremy Skillington, PhD, CEO of Poolbeg Pharma said: “Melioidosis presents a growing threat to health as a result of climate change, and is currently an infectious disease with no approved vaccine and a high mortality rate. At Poolbeg we are focused on targeting the significant global medical need to treat and prevent infectious diseases such as Melioidosis and we look forward to engaging with key scientific opinion leaders involved in the global effort to tackle and eliminate Melioidosis at the upcoming European Melioidosis Congress“.

You might also enjoy reading  Poolbeg Pharma notify that Schroders PLC increase holding to 5.13%
Find more news, interviews, share price & company profile here for:
Poolbeg Pharma plc

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit
Find more news, interviews, share price & company profile here for:
Poolbeg Pharma plc

AIM All Share Index